| Title |
The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1–3 positive lymph nodes in an independent validation study
|
|---|---|
| Published in |
Breast Cancer Research and Treatment, July 2008
|
| DOI | 10.1007/s10549-008-0130-2 |
| Pubmed ID | |
| Authors |
Stella Mook, Marjanka K. Schmidt, Giuseppe Viale, Giancarlo Pruneri, Inge Eekhout, Arno Floore, Annuska M. Glas, Jan Bogaerts, Fatima Cardoso, Martine J. Piccart-Gebhart, Emiel T. Rutgers, Laura J. van’t Veer, On behalf of the TRANSBIG consortium |
| Abstract |
The 70-gene prognosis-signature has shown to be a valid prognostic tool in node-negative breast cancer. Although axillary lymph node status is considered to be one of the most important prognostic factors, still 25-30% of node-positive breast cancer patients will remain free of distant metastases, even without adjuvant systemic therapy. We therefore investigated whether the 70-gene prognosis-signature can accurately identify patients with 1-3 positive lymph nodes who have an excellent disease outcome. |
Mendeley readers
The data shown below were compiled from readership statistics for 124 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 1 | <1% |
| Cuba | 1 | <1% |
| Argentina | 1 | <1% |
| Austria | 1 | <1% |
| Unknown | 120 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 24 | 19% |
| Student > Ph. D. Student | 19 | 15% |
| Other | 15 | 12% |
| Student > Bachelor | 12 | 10% |
| Student > Master | 11 | 9% |
| Other | 30 | 24% |
| Unknown | 13 | 10% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 58 | 47% |
| Biochemistry, Genetics and Molecular Biology | 18 | 15% |
| Agricultural and Biological Sciences | 13 | 10% |
| Computer Science | 4 | 3% |
| Immunology and Microbiology | 2 | 2% |
| Other | 12 | 10% |
| Unknown | 17 | 14% |
Attention Score in Context
This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 October 2013.
All research outputs
#2,928,300
of 22,727,570 outputs
Outputs from Breast Cancer Research and Treatment
#453
of 4,648 outputs
Outputs of similar age
#8,728
of 81,953 outputs
Outputs of similar age from Breast Cancer Research and Treatment
#4
of 25 outputs
Altmetric has tracked 22,727,570 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,648 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.2. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 81,953 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 25 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 84% of its contemporaries.